A cross-sectional observational study to investigate daily symptom variability, effects of symptom on morning activities and therapeutic expectations of patients and physicians in COPD-SUNRISE study;KOAH'da semptomun günlük deǧişkenliǧini, sabah aktiviteleri üzerindeki etkisini ve hastalar ile fizik tedavi uzmanlarının terapötik beklentilerini araştırmak için yapılmış kesitsel bir gözlem çalışması-SUNRISE çalışması

Tuberkuloz ve Toraks

Volumn 59, Issue 4, 2011, Pages 328-339

  Kuyucu, Tülin ^a   Güçlü, Salih Zeki ^b   Şaylan, Bengü ^c   Demir, Cahit ^d   Şenol, Tuncer ^e   Güner, Serdar ^f   Koyuncu, Ejder ^g   Özen, Ferit ^h   Öztürk, Sezai ⁱ   Cangül, Zeki ^j   Aǧanoǧlu, Semih ^k   Özkaya, Şevket ^l   Ocak, Sevilay Çiçek ^m   Akkurt, Hüseyin ⁿ   Intepe, Yavuz Selim ^o   Bayrak, Merve Gülcan ^p   Güler, Tuncay ^q   Bekçi, Taha Tahir ^r   Soyyiǧit, Şadan ^s   Seyfettin, Salim ^t   Kula, Özhan ^u   Akbay, Makbule Özlem ^v   Büyükgöze, Bengü ^w   Asal, Gökhan ^x   Başlilar, Şeyma ^c   Öztürk, Osman ^y   more..

^a Gö üs Cerrahisi E itim ve Ara tirma Hastanesi   (Turkey)

^b Özel Muayenehane   (Turkey)

^c Çocuk ve Ergen Ruh Sa l ve Hastal klar Klini i   (Turkey)

^d Özel Vizyon Fizik Tedavi ve Rehabilitasyon Merkezi   (Turkey)

^e Özel Muayenehane   (Turkey)

^f Turgutlu Devlet Hastanesi   (Turkey)

^g Ayd n Söke Fehime Kocagöz Hospital   (Turkey)

^h Özel Muayenehane   (Turkey)

ⁱ Istanbul Gö üs Hastaliklari Merkezi   (Turkey)

^j Özel Muayenehane   (Turkey)

^k Rize ar Hastanesi   (Turkey)

^l Rize Egitim Arastirma Hastanesi   (Turkey)

^m Esenyurt Devlet Hastanesi   (Turkey)

ⁿ Özel Muayenehane   (Turkey)

^o Yozgat Devlet Hastanesi   (Turkey)

^p Çar amba Devlet Hastanesi   (Turkey)

^q Bolu Izzet Baysal Devlet Hastanesi   (Turkey)

^r Konya Egitim ve Arastirma Hastanesi   (Turkey)

^s Mustafa Yazici Gö üs Hastaliklari Hastanesi   (Turkey)

^t Özel Muayenehane   (Turkey)

^u Özel Muayenehane   (Turkey)

^v Bilecik Bozöyük Devlet Hastanesi   (Turkey)

^w Özel Muayenehane   (Turkey)

^x Antalya Özel Yildiz Andeva Hastanesi   (Turkey)

^y Nallihan Devlet Hastanesi   (Turkey)

more..

Author keywords

COPD; Patient profile; Symptoms; Therapeutic expectations

Indexed keywords

ANTIBIOTIC AGENT; ANTITUSSIVE AGENT; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; LEUKOTRIENE RECEPTOR BLOCKING AGENT; METHYLXANTHINE; MUCOLYTIC AGENT; STEROID; BRONCHODILATING AGENT; EXPECTORANT AGENT;

ADULT; AGED; ARTICLE; AWARENESS; BATH; CARDIOVASCULAR DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLIMBING; COMORBIDITY; COUGHING; DAILY LIFE ACTIVITY; DAILY SYMPTOM VARIABILITY; DISEASE DURATION; DISEASE EXACERBATION; DISEASE SEVERITY; DYSPNEA; EDUCATIONAL STATUS; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORNING DAILY LIFE ACTIVITY; MULTICENTER STUDY; PATIENT ATTITUDE; PHYSICAL MOBILITY; PHYSICIAN ATTITUDE; QUALITY OF LIFE; SMOKING CESSATION; SPUTUM; STEROID THERAPY; SYMPTOM; WHEEZING; CIRCADIAN RHYTHM; CLINICAL TRIAL; CROSS-SECTIONAL STUDY; DISEASE COURSE; HOSPITALIZATION; MIDDLE AGED; MORTALITY; PHYSICIAN; PSYCHOLOGICAL ASPECT;

ACTIVITIES OF DAILY LIVING; ADULT; AGED; AGED, 80 AND OVER; BRONCHODILATOR AGENTS; CIRCADIAN RHYTHM; CROSS-SECTIONAL STUDIES; DISEASE PROGRESSION; DYSPNEA; EXPECTORANTS; FEMALE; HUMANS; MALE; MIDDLE AGED; PHYSICIANS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUALITY OF LIFE; SEVERITY OF ILLNESS INDEX; SMOKING CESSATION;

EID: 84857183710     PISSN: 04941373     EISSN: None     Source Type: Journal    
DOI: 10.5578/tt.3268     Document Type: Article

References (38)

1. Rabe KF, Hurd S, Anzueto A, Barnes PJ, Buist SA, Calverley P, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2007; 176: 532-55.
2. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of Chronic Obstructive Pulmonary Disease. Executive Summary 2006.
3. WHO. World Health Organization. Chronic respiratory diseases. Chronic obstructive pulmonary disease (COPD). 2010 [updated 2010; cited 2 June 2010]; Available from http://www.who.int/respiratory/copd/en/
4. Rennard S, Decramer M, Calverley PMA, Pride NB, Soriano JB, Vermeire PA, et al. Impact of COPD in North America and Europe in 2000: subject's perspective of Confronting COPD International Survey. Eur Respir J 2002; 20: 799-805.
5. Walke LM, Gallo WT, Tinetti ME, Fried TR. The burden of symptoms among community-dwelling older persons with advanced chronic disease. Arc Int Med 2004; 164: 2321-4.
6. Sullivan SD, Ramsey SD, Lee TA. The economic burden of COPD. Chest 2000; 117(Suppl 2): 5-9.
7. Celli BR, MacNee W. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004; 23: 932-46.
8. GOLD. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for diagnosis, management, and prevention of COPD. 2009 [updated 2009; cited 2 June 2010]; Available from http://www.goldcopd.org/Guidelineitem.asp?l1=2&l2=1&intId=2003
9. Stull DE, Wiklund I, Gale R, Capkun-Niggli G, Houghton K, Jones P. Application of latent growth and growth mixture modeling to identify and characterize differential responders to treatment for COPD. Contemp Clin Trials. 2011 [Epub ahead of print] doi:10.1016/j.cct.2011.06.004.
10. American Thoracic Society. Standards for the diagnosis and care of patients with Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med 1995; 152: 77-120.
11. Cazzola M, Donner CF, Hanania NA. One hundred years of chronic obstructive pulmonary disease (COPD)-Republished article. Respir Med 2008; 4: 8-25.
12. Stoller JK, Aboussouan LS. Alpha1-antitrypsin deficiency. Lancet 2005; 365: 2225-36.
13. Antó JM, Vermeire P, Vestbo J, Sunyer J. Epidemiology of chronic obstructive pulmonary disease. Eur Respir J 2001; 17: 982-94.
14. van Schayck CP, Loozen JM, Wagena E, Akkermans RP, Wesseling GJ. Detecting patients at a high risk of developing chronic obstructive pulmonary disease in general practice: cross sectional case finding study. BMJ 2002; 324: 1370-4.
15. Murray CJL, Lopez AD. Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet 1997; 349: 1498-504.
16. Cazzola M, MacNee W, Martinez FJ, Rabe KF, Franciosi LG, Barnes PJ, et al. Outcomes for COPD pharmacological trials: from lung function to biomarkers. Eur Respir J 2008; 31: 416-69.
17. Jones P, Lareau S, Mahler DA. Measuring the effects of COPD on the patient. Respir Med 2005; 99(Suppl B): 11-8.
18. Pauwels RA, Buist AS, Calverley PM, Jenkins CR, Hurd SS, GOLD Scientific Committee. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. Am J Respir Crit Care Med 2001; 163: 1256-76.
19. Ries AL. Impact of chronic obstructive pulmonary disease on quality of life: the role of dyspnea. Am J Med 2006; 119 (10A): S12-S20.
20. Williams SJ. Chronic respiratory illness. In: Titzpatrick R, Newman S (eds). The Experience of Ilness Series. London: Routledge, 1993.
21. Gilbert C, Martin ML, Hareendran A, Bushnell DM, Patrick DL, Schünemann HJ. Capturing Individual Variation in the Experience of Symptoms Reported by Patients with COPD. Poster ATS 2007.
22. Kessler R, Cazzola M, Miravitlles M, Partridge MR, Vogelmeier C, Leynaud D, et al. Variability of symptoms is common in severe COPD: a pan-European cross-sectional study. European Respiratory Society, Annual Congress, Vienna Sept 12-16, 2009 [Eur Resp J 2009; 34(Suppl 53)].
23. Partridge MR, Cazzola M, Kessler R, Miravitlles M, Vogelmeier C, Leynaud D, et al. Diurnal variation of symptoms and impact on morning activities in severe COPD: a pan-European crosssectional study. European Respiratory Society, Annual Congress, Vienna Sept 12-16, 2009 [Eur Resp J 2009;34(Suppl 53)].
24. Partridge MR, Karlsson N, Small IR. Patient insight into the impact of chronic obstructive pulmonary disease in the morning: an internet survey. Curr Med Res Opin 2009; 25: 2043-8.
25. Van Schayck CP, Bindels PJE, Decramer M, Dekhuijzen PNR, Kerstjens HAM, Muris JWM, et al. Making COPD a treatable disease-an integrated care perspective. Respir Med 2007; 3: 49-56.
26. Garcia-Aymerich J, Gómez FP, Antó JM; en nombre del Grupo Investigador del Estudio PAC-COPD. Phenotypic characterization and course of chronic obstructive pulmonary disease in the PAC-COPD Study: design and methods. Arch Broncopneumol 2009; 45: 4-11.
27. Bellamy D, Bouchard J, Henrichsen S, Johansson G, Langhammer A, Reid J, et al. International primary care respiratory group (ICPRG) guidelines: management of chronic obstructive pulmonary disease (COPD). Prim Care Respir J 2006; 15: 48-57.
28. Celli BR, Cote DG, Marín JM, Casanova C, Montes de Oca M, Méndez RA, et al. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med 2004; 350: 1005-12.
29. Sobradillo Pena V, Miravitlles M, Gabriel R, Jime ́nez-Ruiz CA, Villasante C, Masa JF, et al. Geographical variations in prevalence and underdiagnosis of COPD. Results of the IBERPOC multicentre epidemiological study. Chest 2000; 118: 981-9.
30. Miravitlles M, Ferrer M, Pont A, Luis Viejo J, Fernando Masa J, Gabriel R, et al. Characteristics of a population of COPD patients identified from a population-based study. Focus on previous diagnosis and never smokers. Respir Med 2005; 99: 985-95.
31. Watson L, Vonk JM, Löfdahl CG, Pride NB, Pauwels RA, Laitinen LA, et al; European Respiratory Society Study on Chronic Obstructive Pulmonary Disease. Predictors of lung function and its decline in mild to moderate COPD in association with gender: results from the Euroscop study. Respir Med 2006; 100: 746-53.
32. Voll-Aanerud M, Eagan TM, Wentzel-Larsen T, Gulsvik A, Bakke PS. Respiratory symptoms, COPD severity, and health related quality of life in a general population sample. Respir Med 2008; 102: 399-406.
33. Nguyen HQ, Donesky-Cuenco D, Carrieri-Kohlman V. Associations between symptoms, functioning, and perceptions of mastery with global self-rated health in patients with COPD: a cross-sectional study. Int J Nurs Stud 2008; 45: 1355-65.
34. Miravitlles M, Anzueto A, Legnani D, Forstmeier L, Fargel M. Patient's perception of exacerbations of COPD-the PERCEIVE study. Respir Med 2007; 101: 453-60.
35. Miravitlles M, Llor C, Naberan K, Cots JM, Molina J. Variables associated with recovery from acute exacerbations of chronic bronchitis and chronic obstructive pulmonary disease. Respir Med 2005; 99: 955-65.
36. Wilson R, Jones P, Schaberg T, Arvis P, Duprat-Lomon I, Sagnier PP. Antibiotic treatment and factors influencing short and long term outcomes of acute exacerbations of chronic bronchitis. Thorax 2006; 61: 337-42.
37. Wouters EF, Breyer MK, Rutten EP, Graat-Verboome L, Spruit MA. Co-morbid manifestations in COPD. Resp Med 2007; 3: 135-51.
38. The National Collaborating Centre for Chronic Conditions. National clinical guideline on management of COPD in adults in primary and secondary care. Thorax 2004; 59(Suppl 1): 1-232.